Emergent BioSolutions to Develop Two COVID-19 Treatments

Maryland-based Emergent BioSolutions announced that it is developing two plasma- based product candidates to treat and prevent COVID-19. 

COVID-HIG will be manufactured from human plasma with antibodies to the virus as a potential treatment for severe hospitalized patients and protection for at-risk individuals.

COVID-EIG will use plasma of immunized horses with antibodies to the virus, which will be used as a potential treatment for severe hospitalized patients.